Zeaxanthin: History and Discovery

Unlike a herb, zeaxanthin has no folk healer and no ancient apothecary — it is a molecule, and its history is the history of chemistry and vision science slowly working out what it is and what it does. The story runs along two tracks that only met late. One track is chemical: the early-twentieth-century chemists who first separated the yellow plant pigments, named this one after the corn it colours, and worked out its structure. The other is medical: the century-long effort to explain why the very centre of the human retina is stained yellow — a puzzle that began with George Wald in 1945 and was only solved when Bone and Landrum chemically identified the macular pigment as lutein and zeaxanthin in the 1980s. This article follows what the record actually supports. Where a date or a name is firmly documented we give it; where attribution is shared, gradual, or argued over, we say so.

Table of Contents

  1. A Pigment Named for Corn
  2. The Early Carotenoid Chemists
  3. Working Out the Structure
  4. The Yellow Spot: Wald, 1945
  5. Naming the Macular Pigment: Bone & Landrum, 1985
  6. The Third Carotenoid: Meso-Zeaxanthin
  7. From Pigment to Prescription: AREDS and AREDS2
  8. What the History Tells Us
  9. Research Papers and References
  10. Connections
  11. Featured Videos

A Pigment Named for Corn

The name zeaxanthin records exactly where the compound was first noticed. It joins two parts: Zea, from Zea mays, the botanical name for maize (corn), and xanthos, the Greek word for "yellow." Zeaxanthin is the principal pigment that makes yellow corn yellow, and it is from corn that the molecule took its name. Read literally, then, the word means something like "the yellow substance of maize" — a small, accurate label rather than a marketing flourish.

That naming places zeaxanthin firmly within the chemistry of its day. It belongs to the carotenoids, the large family of yellow, orange, and red pigments found throughout plants, algae, and many animals, and more specifically to the xanthophylls — the carotenoids that contain oxygen. The very word "xanthophyll" (Greek for "yellow leaf") was coined in the nineteenth century for the yellow pigments of autumn foliage, long before anyone could say what individual molecules made up that yellow. Zeaxanthin is one of the molecules that turned out to be hiding inside that old, general name.

It is worth being clear about what kind of history this is. Zeaxanthin was never "invented," and it has no single discoverer in the way a drug might. It is a natural pigment that plants and microbes have been making for hundreds of millions of years, and that humans have eaten — in corn, in egg yolk, in goji berries, in leafy greens — for as long as there have been humans. What follows is not the story of where zeaxanthin came from, but of how science came to recognise it, name it, map its structure, and finally understand the job it does in the human eye.

Back to Table of Contents

The Early Carotenoid Chemists

Zeaxanthin emerged into scientific view during a remarkable burst of work on plant pigments in the first decades of the twentieth century. The decisive early figure was the German chemist Richard Willstätter, who would win the 1915 Nobel Prize in Chemistry for his work on plant pigments. In 1907, Willstätter and his collaborator clearly distinguished two kinds of pigment that had previously been lumped together: carotene, a pure hydrocarbon, and xanthophyll, an oxygen-containing pigment. This 1907 separation is the conceptual starting point for zeaxanthin's chemistry: it established that the "yellow leaf" pigments were not one substance but a family, and that the oxygen-bearing xanthophylls — the group zeaxanthin belongs to — were chemically distinct from the carotenes.

Separating the individual xanthophylls from one another was a harder problem, and it was solved by the technique that would transform the whole field: chromatography. The method had been introduced by the botanist Mikhail Tswett early in the century precisely to separate leaf pigments, and as it matured it became possible to pull apart pigments that were almost chemically identical. By the early 1930s, chromatographic work on the xanthophylls of plants and of egg yolk was distinguishing zeaxanthin from its near-twin lutein — two pigments so similar that only a careful separation could tell them apart.

The names attached to this early phase — Willstätter, Tswett, and the structural chemists who followed — belong to the founding of carotenoid science as a whole rather than to zeaxanthin alone. That is the honest shape of the record: there is no single "moment of discovery" for zeaxanthin, but rather a stretch of years in which improving chemistry made it possible to isolate this particular yellow pigment, recognise it as a distinct compound, and give it the name it still carries.

Back to Table of Contents

Working Out the Structure

Knowing that zeaxanthin existed was one thing; knowing its molecular structure was another, and that achievement belongs largely to the Swiss chemist Paul Karrer and his school at the University of Zurich. During the late 1920s and early 1930s Karrer carried out a celebrated series of investigations — published under the running title Pflanzenfarbstoffe ("Plant Pigments") in the journal Helvetica Chimica Acta — in which he worked out the chemical constitution of the carotenoids one after another, including the xanthophylls. For this work on the structure of the carotenoids and of vitamin A, Karrer shared the 1937 Nobel Prize in Chemistry.

Out of that work came the structural picture of zeaxanthin still used today. Its chemical formula is C₄₀H₅₆O₂: a long central chain of conjugated double bonds — the feature that makes carotenoids coloured and makes them good at absorbing light and quenching reactive oxygen — capped at each end by a ring carrying a single oxygen, in the form of a hydroxyl group. Those two oxygen atoms are exactly what distinguish a xanthophyll like zeaxanthin from a pure-hydrocarbon carotene such as beta-carotene.

The structural work also revealed one of the most important facts about zeaxanthin: it is an isomer of lutein. The two molecules share the identical formula C₄₀H₅₆O₂ and differ only in the position of a single double bond in one of the end rings. This near-identity, settled by the early structural chemists, is the reason the two pigments are almost always discussed as a pair — and, as the later sections show, it is also the key to a subtle biological trick the human eye performs with them. Notably, because zeaxanthin's rings carry only hydroxyl oxygens and not the ring structure that the body can cleave into retinol, zeaxanthin has no vitamin A activity; unlike beta-carotene, it was never a candidate provitamin, and its eventual importance would lie in an entirely different direction.

Back to Table of Contents

The Yellow Spot: Wald, 1945

While chemists were dissecting plant pigments, anatomists had long known a curious fact about the human eye: the very centre of the retina, the small area of sharpest vision, is stained a faint yellow. Early anatomists named it the macula lutea — literally the "yellow spot." For most of its history the identity of that yellow colour was unknown.

The pivotal step came from the American scientist George Wald, later a Nobel laureate for his work on the chemistry of vision. In 1945, in a paper in the journal Science titled "Human Vision and the Spectrum," Wald reported that the yellow pigment of the human macula is a carotenoid of the xanthophyll family. He measured how the macular pigment absorbed light — finding it took up blue light between roughly 430 and 490 nanometres, peaking near 460 — and recognised that this absorption pattern matched that of a dietary xanthophyll. Because animals cannot manufacture carotenoids, Wald's identification carried a striking implication: the pigment protecting the centre of our vision must come from the food we eat.

Wald's 1945 finding reframed the macula. The yellow was not an incidental stain but a deliberately concentrated dietary pigment, sitting exactly where the eye gathers the most light. What Wald could not yet say was precisely which xanthophylls made up that pigment. His instruments could identify the family; pinning down the individual molecules would take another forty years and a generation of better chemistry.

Back to Table of Contents

Naming the Macular Pigment: Bone & Landrum, 1985

The molecular answer to Wald's question came from the laboratory of Richard Bone and John Landrum in the United States, working with the separating power of high-performance liquid chromatography (HPLC), a technique far beyond anything available in 1945. In 1985, in the journal Vision Research, Bone, Landrum, and Tarsis published a paper plainly titled "Preliminary identification of the human macular pigment" — the work generally credited with first chemically identifying the macula's yellow pigment as a mixture of lutein and zeaxanthin. The forty-year-old riddle of the yellow spot finally had named molecules in it.

This identification is the single most consequential event in zeaxanthin's history, because it connected the molecule to a human organ and a human disease. Once it was known that zeaxanthin and lutein are the macular pigment, every later question followed: how the eye selects and concentrates them, why they sit where they do, whether eating more of them could protect the retina, and whether they might be used against age-related macular degeneration. Bone and Landrum, often working together over many years, went on to map these carotenoids in the retina in detail — including, in a 1997 study in Experimental Eye Research, charting how the proportions of the different carotenoids shift from the very centre of the macula outward.

A word on dating, in the interest of accuracy: the chemical identification of the macular carotenoids is sometimes attributed to 1985 and sometimes to follow-up work later in the 1980s, because it was a refinement rather than a single overnight result. The 1985 Vision Research paper is the firmly documented landmark and the one usually cited as the first identification; the late-1980s papers sharpened and confirmed it. We present 1985 as the milestone while noting that, as with much real science, the certainty arrived in stages.

Back to Table of Contents

The Third Carotenoid: Meso-Zeaxanthin

The story took an unexpected turn a few years later. When Bone, Landrum, and colleagues examined the stereochemistry of the macular carotenoids — the precise three-dimensional handedness of the molecules — they found something that was not supposed to be there. Reporting in Investigative Ophthalmology & Visual Science in 1993, they showed that the centre of the macula contains not two but three carotenoids: dietary lutein, dietary zeaxanthin, and a third pigment, meso-zeaxanthin, which is barely present in the ordinary diet at all.

The puzzle of where meso-zeaxanthin came from had an elegant answer. Meso-zeaxanthin is a stereoisomer of ordinary zeaxanthin — the same atoms connected the same way, but with a different spatial arrangement at one carbon — and the evidence indicated that the retina makes its own meso-zeaxanthin by converting dietary lutein, right at the foveal centre. The researchers even demonstrated chemically that converting lutein in this way yields specifically the meso form. This explained an otherwise baffling observation: in the bloodstream lutein outweighs zeaxanthin, yet in the central retina the zeaxanthin-type pigments come out ahead — because the eye is quietly manufacturing extra zeaxanthin on site.

The discovery of meso-zeaxanthin completed the modern picture of the macular pigment as a trio of carotenoids, and it would later shape how eye-health supplements were designed. It is a good example of how zeaxanthin's history kept opening new questions: each time the chemistry improved, the eye turned out to be doing something more sophisticated than anyone had assumed.

Back to Table of Contents

From Pigment to Prescription: AREDS and AREDS2

Identifying zeaxanthin as a macular pigment raised an obvious practical question: if these carotenoids protect the retina, could supplementing them help people with age-related macular degeneration (AMD), the leading cause of irreversible central vision loss in older adults? Answering it took two large clinical trials run by the United States National Eye Institute.

The first, the Age-Related Eye Disease Study (AREDS), reported in 2001 that a supplement of vitamin C, vitamin E, beta-carotene, zinc, and copper reduced the risk of progression to advanced AMD in at-risk people. But that formula had a problem: it relied on high-dose beta-carotene, which earlier trials had linked to increased lung-cancer risk in smokers. And, tellingly, the original AREDS formula contained no lutein or zeaxanthin — purified forms of the actual macular pigments simply were not available when the trial was designed.

The follow-up trial, AREDS2, published in JAMA in 2013, was built to fix exactly that. In more than 4,000 participants it tested whether lutein (10 mg) plus zeaxanthin (2 mg) could safely replace beta-carotene. They could: the lutein-and-zeaxanthin formula gave equivalent or better protection without the cancer signal, and the benefit was greatest in people whose diets had been lowest in these carotenoids to begin with. As a direct result, the standard AMD supplement formula was rewritten — beta-carotene out, lutein and zeaxanthin in. This is the moment zeaxanthin crossed from being an interesting pigment to being a routine, evidence-based ingredient in eye care. (AREDS2 showed slowing of progression in people who already had intermediate-to-advanced AMD; it did not show that the formula prevents AMD in healthy eyes or restores lost vision.)

The fuller account of the science — the trials, the mechanisms, the dosing, and the cautions — is given on the main Zeaxanthin page. Here it stands as the final chapter of the discovery story: the point at which a century of chemistry and vision science produced a concrete clinical recommendation.

Back to Table of Contents

What the History Tells Us

Zeaxanthin's history is unusually clean in one respect: nearly every milestone in it is a documented experiment by a named scientist, published in a dateable paper. There is no folklore to untangle, no contested ancient origin. The chemists Willstätter and Karrer made it a known, structurally defined molecule; George Wald, in 1945, showed that a xanthophyll pigments the centre of human vision; Bone and Landrum, in 1985, proved that the pigment is lutein and zeaxanthin; the same group uncovered meso-zeaxanthin in 1993; and the AREDS2 trial, in 2013, turned all of this into clinical practice.

Two honest cautions belong at the end. First, the dates of a discovery are firmer than the boundaries of its benefits: knowing exactly when and by whom zeaxanthin was identified does not by itself prove what any dose will do for an individual person's eyes, which is what the clinical trials, not the history, are for. Second, the most reliable claims about zeaxanthin concern the eye; its possible roles elsewhere, such as in the brain, are genuinely promising but newer and less settled, and should be described as such. The thread from a yellow stain in the retina to a named molecule in a clinical trial is unbroken and well documented — and following it carefully, without overstating any single link, is the point of knowing the history at all.

Back to Table of Contents

Research Papers and References

The list below combines the landmark primary papers in zeaxanthin's history with key reviews and curated PubMed topic-search links. The early structural chemistry of Richard Willstätter (1907) and Paul Karrer (the Pflanzenfarbstoffe series in Helvetica Chimica Acta, early 1930s) is described in the article as foundational historical work; those original German-language papers predate digital identifiers. Author names, titles, and journals below are given as plain text; only the stable DOI, PMID, or archive link is hyperlinked, and each opens in a new tab.

  1. Wald G. Human vision and the spectrum. Science. 1945;101(2635):653–658. — doi:10.1126/science.101.2635.653 · PMID: 17777531
  2. Bone RA, Landrum JT, Tarsis SL. Preliminary identification of the human macular pigment. Vision Research. 1985;25(11):1531–1535. — PMID: 3832576
  3. Bone RA, Landrum JT, Hime GW, Cains A, Zamor J. Stereochemistry of the human macular carotenoids. Investigative Ophthalmology & Visual Science. 1993;34(6):2033–2040. — PMID: 8491553
  4. Bone RA, Landrum JT, Friedes LM, et al. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Experimental Eye Research. 1997;64(2):211–218. — doi:10.1006/exer.1996.0210 · PMID: 9176055
  5. Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annual Review of Nutrition. 2003;23:171–201. — doi:10.1146/annurev.nutr.23.011702.073307
  6. Bernstein PS, Li B, Vachali PP, et al. Lutein, zeaxanthin, and meso-zeaxanthin: the basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Progress in Retinal and Eye Research. 2016;50:34–66. — doi:10.1016/j.preteyeres.2015.10.003 · PMID: 26541886
  7. Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005–2015. — doi:10.1001/jama.2013.4997
  8. Zeaxanthin and lutein — history and identification of the macular pigment — PubMed: macular pigment lutein and zeaxanthin identification
  9. Carotenoid chemistry and structure — history — PubMed: carotenoid and xanthophyll structure history

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents